A phase II trial of PNT 2258 in combination with standard-of-care treatment regimen as second line treatment in 'transplant ineligible' patients with diffuse large B-cell lymphoma

Trial Profile

A phase II trial of PNT 2258 in combination with standard-of-care treatment regimen as second line treatment in 'transplant ineligible' patients with diffuse large B-cell lymphoma

Planning
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs Rosomidnar (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms Granite
  • Most Recent Events

    • 09 Jan 2017 According to a Sierra Oncology media release, this trial was originally conducted by ProNAi Therapeutics, Inc. but later on this company's name changed to Sierra Oncology.
    • 08 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top